@LeivaOrly What’s worse is when the anatomy is defined and then you find severe disease as the interventionalist and say medical therapy when they have >70% stenosis and usually
90 plus percent. As the IC in these cases we are ridiculed if we stent and ridiculed by patient if we dont
@agtruesdell@MichaelMegalyMD Important for all when they take a new job or first job. Know where the equipment is. Most have never deployed coils or dealt with perforations. Need to know your supplies. 0.14 coils are not the norm in most labs
@markiewicz_md@jcgeorgemd@mmamas1973@JayMathewsMD Have the same patient less than one month ago. Switched to warfarin and will know soon whether it did anything. Good luck and I’ll keep you updated
@aspergian1@HeartOTXHeartMD Not only that but then when the patient is not sent home on dual antiplatelet with a diagnosis of NSTEMI it triggers a trigger saying patient not appropriately treated by coders……
@CardioNerdsJC Do people have concern about generalizability of people adhering to Ticag? People usually good in trials but the shortness of breath and discontinuation is concerning to me #cardiojc
@MelissaJoy1228@CardioNerdsJC There is plenty of data for ACS patients in general. ACS is not all the same. UA vs NSTEMI vs STEMI. Would love a trial that doesn’t include UA but would be hard to get enough patients
@CardioNerdsJC Strongly believe that STEMI patients are a different subset. TICO-STEMI also showed a problem with monotherapy. Would not advocate to shorten DAPT in these patients unless absolutely necessary or very HBR
@CardioNerdsJC Yes this is standard but does BARC 2 bleeding have the same morbidity and mortality as 3 and 5? Is there any signal that BARC 2 is an important marker of problems to come?
@CardioNerdsJC STOP DAPT 2 - ACS failed to meet noninferiority. Problem with clopidogrel is the heterogeneity of response with 25% non responders. #cardiojc